{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temozolomide+Oral+Product&page=2", "query": { "intervention": "Temozolomide Oral Product", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temozolomide+Oral+Product&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T00:50:01.652Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04900792", "title": "A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Ferumoxytol injection", "type": "DRUG" }, { "name": "Pharmacological ascorbate", "type": "DRUG" }, { "name": "External beam radiation therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Bryan Allen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-02-28", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900792" }, { "nct_id": "NCT01605162", "title": "Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wild Type BRAF Stage IV Melanoma", "Unresectable Stage III Melanoma" ], "interventions": [ { "name": "TMZ", "type": "DRUG" }, { "name": "E7016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-05", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2016-07-28", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605162" }, { "nct_id": "NCT02046187", "title": "Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma (GBM)" ], "interventions": [ { "name": "Ketogenic Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "RADIATION", "DRUG" ], "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 14, "start_date": "2013-10", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2021-06-16", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02046187" }, { "nct_id": "NCT00316849", "title": "Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "pharmacological study", "type": "OTHER" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "temsirolimus", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2006-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Clive, Iowa • Des Moines, Iowa + 2 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Clive", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316849" }, { "nct_id": "NCT03930771", "title": "Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Pituitary Adenomas" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-05-21", "completion_date": "2021-10-01", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03930771" }, { "nct_id": "NCT04388475", "title": "Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Malignant Glioma", "Brain Glioblastoma" ], "interventions": [ { "name": "OKN-007", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oblato, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2020-06-12", "completion_date": "2025-03-05", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388475" }, { "nct_id": "NCT04239092", "title": "9-ING-41 in Pediatric Patients With Refractory Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Cancer", "Refractory Neoplasm", "Cancer Pediatric", "Refractory Tumor", "Pediatric Cancer", "Pediatric Brain Tumor", "Neuroblastoma", "Neuroblastoma Recurrent", "Pediatric Lymphoma", "Pediatric Meningioma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 40, "start_date": "2020-06-05", "completion_date": "2025-07-07", "has_results": false, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 9, "location_summary": "San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04239092" }, { "nct_id": "NCT00539591", "title": "Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Peginterferon alfa-2b", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Recombinant interferon alfa-2b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 29, "start_date": "2008-05-09", "completion_date": "2031-05", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 3, "location_summary": "San Diego, California • Memphis, Tennessee • Houston, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00539591" }, { "nct_id": "NCT05902169", "title": "Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "GBM" ], "interventions": [ { "name": "SonoCloud-9 (SC9)", "type": "DEVICE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "CarThera", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2024-01-29", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902169" }, { "nct_id": "NCT00492141", "title": "Aerosol L9-NC and Temozolomide in Ewing's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing's Sarcoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "L9-NC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 10, "start_date": "2006-06", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-08-02", "last_synced_at": "2026-09-30T00:50:01.652Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492141" } ] }